<DOC>
	<DOCNO>NCT00882726</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics , pharmacodynamics CNTO 3649 follow single dose healthy adult follow multiple dos patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>A Study Safety , Pharmacokinetics , Pharmacodynamics CNTO 3649 Healthy Adults Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , placebo control , double-blind ( neither physician patient know name assign study medication ) , ascending-dose study ass safety , tolerability , immune response , pharmacokinetics ( body drug ) , pharmacodynamics ( drug body ) CNTO 3649 . The study population consist approximately 80 healthy participant ( Part 1 ) approximately 36 type 2 diabetic patient ( Part 2 ) . All participant randomize CNTO 3649 placebo ratio 3:1 . Out 80 healthy participant , 48 participant receive single dos CNTO 3649 ( 6 dose level ) placebo intravenous infusion ( directly vein ) 32 participant receive single dos CNTO 3649 ( 4 dose level ) placebo subcutaneous ( skin ) injection . All 36 diabetic patient receive multiple dos CNTO 3649 ( 3 dose level ) placebo subcutaneous injection . There screen period 30 day 45 day healthy participant diabetes patient , respectively . Healthy participant study 9 week . Diabetic patient study 12 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Part 1 ( healthy participant ) : Demonstrate understand study sign inform consent form Healthy male female subject clinically relevant abnormality determine medical history , physical examination , blood chemistry assessment , hematologic assessment include complete blood count , coagulation test , urinalysis , measurement vital sign , ECG Age 18 55 Have body mass index ( BMI ) 18.5 30 kg/m2 weight 50 100 kg Part 2 ( patient type 2 diabetes ) : Type 2 Diabetic male female subject diagnose least 12 month prior screen stably manage &gt; = 3 month HbA1c level within range 6 % 10 % treat diet exercise alone , 6 % 9 % therapy BMI 18.5 37 kg/m2 . Age 18 65 year . Part 1 ( healthy participant ) : Currently history clinically significant medical illness medical disorder investigator considers exclude subject Part 2 ( patient type 2 diabetes ) : Any clinically significant medical illness medical disorder ( exception diagnosis T2DM , wellcontrolled hypertension , wellcontrolled dyslipidemia ) investigator considers exclude subject . History 3 day insulin use last 3 month , thiazolidinedione medication , alpha glucosidase inhibitor , exenatide within 3 month screen visit . History clinically significant acute chronic diabetic complication . History severe hypoglycemic reaction 6 month prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>CNTO 3649</keyword>
	<keyword>safety</keyword>
	<keyword>Phase I</keyword>
	<keyword>healthy adult</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>